INTRODUCTION
Evidence has accumulated that sex hormones play a potential role in the development of colorectal cancer (1, 2) . In a recent meta-analysis of four randomized controlled trials, eight cohorts and eight case-control studies, ever use of a combined estrogen-progestagen therapy was associated with a 26% decreased risk for colorectal cancer (odds ratio (OR) = 0.74, 95% confidence interval (CI) 0.68-0.81) and a similar result was observed with ever use of estrogen monotherapy (OR = 0.79, 95% CI 0.69-0.91). (3) . The results of a meta-analysis investigating the association between ever use of oral contraceptives and colorectal cancer risk indicated also an inverse relationship, with a risk reduction of 19% (OR = 0.81, 95% CI
0.72-0.92). (4).
The associations observed with reproductive factors such as age at menarche, parity, and age at menopause have been conflicting and the majority of studies reported null associations (5, 6) . The inconsistent results could be caused by differing associations of reproductive factors with colorectal cancer risk depending on the molecular characteristics of the tumor. A potential mediator of estrogen effects is the estrogen receptor beta (ESR2), which is the primarily expressed estrogen receptor in the large intestine (1) . Loss of ESR2 expression in tumor tissue of colorectal cancer patients has been associated with poorer differentiation of tumors and more advanced cancer stages (7) (8) (9) (10) . However, it has also been postulated that endogenous and exogenous sex hormones may have differential effects on the development of colorectal cancer (6) , as high levels of endogenous estrogens have been found to be associated with an increased risk for colorectal cancer (11, 12) .
Colorectal cancer risk associated with exogenous hormone use as well as with reproductive factors may differ depending on the presence of ESR2 expression in the tumor. 5 differential by ESR2 expression and is greater for tumors expressing ESR2. This has not been investigated so far and is addressed in the present study.
MATERIALS AND METHODS

Study Population
Colorectal cancer cases and controls were drawn from the DACHS (Darmkrebs:
Chancen der Verhütung durch Screening) study, a population-based case-control study conducted in the southwest of Germany. Details of the study design have been reported elsewhere (13, 14) . Briefly, cases were patients aged at least 30 years, with a first histologically confirmed diagnosis of primary invasive colorectal cancer (ICD-10 codes C18-C20) between January 2003 and December 2007, and recruited during first hospitalization due to cancer treatment or shortly afterwards at their homes. The controls were selected randomly from lists of population registries and frequency matched according to age, sex, and county of residence. Additional inclusion criteria for both cases and controls were proficiency in the German language, mental and physical ability to participate in a personal interview of about one hour, no previous history of colorectal cancer, and residency in the study region.
Written informed consent was obtained from every participant. The study was approved by the ethical committees of the University of Heidelberg and the Medical Chambers of Baden-Württemberg and Rhineland-Palatinate. 6 factors as well as reproductive factors in face-to-face interviews with the participants.
Additionally, discharge letters and pathology reports were obtained. Regarding exogenous hormones, information collected on menopausal hormone therapy use included start and end of therapy, hormone preparation, dose, regimen, and mode and route of application. The standardized questionnaire asked for up to eight sequential phases of menopausal hormone therapy use, and a change in medication was recorded as starting a new phase. The interviewers presented a medication list as memory aid to identify the preparations.
Information collected on use of oral contraceptives included age at initial use and total duration. Self-reported menopausal hormone therapy use was validated by medical records requested from the women's physicians for every woman recruited between 2003 and 2006 (15) . Based on statistics of colorectal cancer patients treated in the hospitals, the participating patients accounted for 50% of the expected number of eligible cases in the study region. The response rate among eligible control individuals was likewise slightly above 50%. To evaluate the ESR2 expression of the tumor tissue and non-tumorous mucosa, a 3-level scoring system was applied (based on Konstantinopoulos et al. (7)) that involved staining frequency and intensity. Samples with less than 10% of the cell nuclei showing strong positive staining or with less than 50% of the nuclei showing weak positive staining were regarded as ESR2-negative. ESR2-positivity was defined as weak staining of more than 50% of the cell nuclei or strong positive staining in at least 10% of the cell nuclei. The scoring was performed independently by two pathologists. The preparation of the immunohistochemistry as well as the scoring was performed blinded to other case characteristics. Results of the scoring were identical for 96.8% of the samples and discordant results were resolved by an additional joint review of the respective sample.
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Variable definitions
To define variables, the reported history at the reference date was used (date of interview for controls and date of diagnosis for cases). Women were defined as "ever users" of hormone therapy and oral contraceptives when the respective reported total duration of use was at least three months. If the last use of hormone therapy was less than six months ago before the reference date, it was defined as "current use".
Statistical analysis
The statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC, USA). Two sided-tests were carried out and a P-value of <0.05 was regarded as significant.
Pearson's χ 2 test and the Wilcoxon rank-sum test were applied to test differences between ESR2-negative and ESR2-positive cases and between cases and controls.
To assess heterogeneity in colorectal cancer risk by ESR2 status, logistic regression models with tumoral ESR2 status as the outcome were used in case-case analyses. It should be pointed out, that for a dichotomous tumor characteristic like the ESR2 status, the OR from the case-case analysis corresponds to the ratio of the two subtype specific case-control ORs for association with the risk factor of interest. We performed case-control analyses using multinomial logistic regression models to evaluate colorectal cancer risk according to disease subtype (ESR2-negative disease, ESR2-positive disease) and calculated ORs and the respective 95% CIs.
In case-control analyses, all models were adjusted for age and county of residence.
Additional covariates were considered as potential confounders if they modified the OR associated with ever use of hormone therapy by at least 5%. The models included ever colorectal endoscopy, former body mass index (5-14 years before reference date), ever
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diagnosis of diabetes, ever general health checks, physical activity and ever use of oral contraceptives as well as hormone therapy. Although we investigated several exposures, we did not try to incorporate a different set of confounders for each exposure. We regarded most of the covariates that modified the OR associated with ever use of hormone therapy to be also potential confounders for all of the investigated exposure associations, perhaps with the exception of physical activity.
The following variables were considered as confounders, but they did not change the OR associated with ever use of hormone therapy substantially and were therefore not included in the model: having a first degree relative diagnosed with colorectal cancer, ever regular use of non-steroidal anti-inflammatory drugs (2+ times/week, ≥1 year), education (three categories), ever breastfed, number of pregnancies, pack-years of smoking (in categories of 10 pack-years), average alcohol consumption in the last year before diagnosis (g/day in quartiles). For assessing associations with hormone therapy by type, we used never use of any hormone therapy as the reference category and therefore adjusted for other types of hormone therapy, as appropriate. Models used in case-case analyses included the same covariates as the models used in case-control analyses, except for the matching factor county of residence.
Participants with missing values in the explanatory variables or the response variable were excluded from analyses. 
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RESULTS
The immunohistochemical analysis of ESR2 expression was successful in 88.5% of the 503 cases samples. Reasons for unsuccessful measurements were an uninformative positive control and loss of cores. Of the 445 samples with successful measurement, 219 (49.2%) were ESR2-negative and 226 (50.8%) were ESR2-positive according to defined thresholds.
The distributions of selected characteristics of the study population are shown in Table   1 . Cases were more likely than controls to have a higher body mass index, higher alcohol intake, less physical activity, a history of diabetes, no history of colorectal endoscopies, less regular intake of non-steroidal anti-inflammatory drugs, less use of hormone therapy as well as of oral contraceptives. The distributions of selected variables did not differ significantly between ESR2-negative cases and ESR2-positive cases or between cases with known ESR2 status and unknown ESR2 status.
As previously reported for the DACHS study (15) , ever use of hormone therapy was associated with a reduced risk for colorectal cancer (odds ratio (OR) = 0.63, 95% confidence interval (CI) 0.46-0.85). There was no significant association between ever use of oral contraceptives and colorectal cancer risk (OR = 0.74, 0.54-1.03). When considering specific types of hormone therapy, the inverse risk associations with ever use of estrogen-progestagen therapy by ESR2 status were comparable to that observed for any hormone therapy, being non-significantly stronger for ESR2-positive tumors. The opposite pattern by ESR2 status was observed with ever use of estrogen monotherapy. Here, a non-significantly stronger inverse association with colorectal cancer risk was observed for ESR2-negative tumors (OR = 0.32, 95% CI 0.14-0.74) compared to ESR2-positive tumors (OR = 0.62, 95% CI 0.33-1.15; P heterogeneity = 0.36).
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The associations between reproductive factors and colorectal cancer risk did not differ significantly according to ESR2 expression. However, having four or more full-term pregnancies compared to one full-term pregnancy was significantly inversely associated with risk for developing ESR2-positive tumors (OR = 0.47, 95% CI 0.23-0.95) as well as menarche at age 14 compared to menarche at age 12 or younger (OR = 57, 95% CI 0.34-0.94).
DISCUSSION
The present study provides first evidence that the association between exogenous hormone use and colorectal cancer risk may be differential according to ESR2 expression in Whether ESR2 expression in colorectal cancer is associated with microsatellite status remains to be clarified, as Wong et al. found that ESR2 isoform 1 expression was decreased in microsatellite stable colorectal cancer compared to microsatellite instable colorectal cancer, but no differences in expression were observed for isoform 2 and isoform 5 (22). We also did not observe differences in ESR2 expression according to microsatellite status in the DACHS study population (10 
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use of menopausal hormone therapy and colorectal cancer risk according to CDKN1A expression (19). Current use of hormone therapy was associated with a significantly reduced risk for CDKN1A-negative colorectal cancer but not with CDKN1A-positive colorectal cancer. These results were not consistent with findings from experimental studies, where CDKN1A-expression was found to be upregulated in presence of ESR2, suggesting that CDKN1A is a target gene of ESR2-signaling (23, 24) .
In experimental cell line and animal studies, protective effects of female sex hormones regarding colorectal carcinogenesis were found to be mediated by ESR2 (24) (25) (26) (27) (28) (29) . Therefore, it is biologically plausible that exogenous hormones interact with ESR2 and downregulate the growth of neoplastic cells in the colorectal mucosa. Once the cells lose the expression of ESR2, e.g. by acquired mutations or aberrant methylation, the protective effect of exogenous hormones may be attenuated. .
In our study, users of oral contraceptives had a higher prevalence of hormone therapy use than non-users of oral contraceptives (57.2% ever hormone therapy users among ever users of oral contraceptives compared to 29.9% among never users of oral contraceptives). Table 1 ). Thus, availability of ESR2 status is unlikely to have had a major impact on the results. Apart from women without information on ESR2 status, a small proportion (4.4%-9.6%) of individuals did not contribute to the analyses due to missing information on exposures or covariates. Since there is no indication that the respective data are not missing at random, it seems unlikely that excluding participants with missing data biased our results.
Another potential source of selection bias is the incomplete and potentially differential participation of eligible cases and controls. As discussed in detail elsewhere (33), incomplete ascertainment of cases was primarily due to work overload of physicians in charge of case notifications and to lower compliance of home interviews in case of recruitment after discharge, and is unlikely to be related to history of exogenous hormone use. On the other hand, patients with advanced disease were less likely to participate in the study and ESR2-negativity is more prevalent in advanced colorectal cancer (7, 8, 10) . However, differences in colorectal cancer risk associated with the use of oral contraceptives and hormone therapy according to disease stage are not established (3-6) and were also not observed in the present study (Supplementary Table 2 ). Therefore, this particular selection bias in cases is unlikely to strongly affect our results.
Half of the non-participating controls provided information by completing a short questionnaire. They were less likely to have undergone preventive health checks and less likely to have used hormone therapy, thus giving some indication for possible overestimation of the protective effect of hormone therapy. This was partly controlled for by adjustment for general health check-ups. The prevalence of ever hormone therapy use among controls was comparable to the prevalence among the general female German population in this age-range, estimated using external prescription data (34). Also recall bias is unlikely to have 
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substantially affected the findings regarding hormone therapy use, since a former analysis in the DACHS sample found that the agreement between self-reported and the record based duration of hormone therapy use was similarly good in cases and controls (15) .
ESR2 expression was independently assessed by two pathologists. A common concern raised by using tissue microarrays is whether the punched tumor samples are representative for the whole sample. Validation studies showed that two cores of 0.6 mm diameter lead to a sufficient concordance with the whole sample section for various types of tissue, including colorectal cancer (35, 36).
The applied antibody (14C8) has been shown to be useful for the immunohistochemical assessment of ESR2 expression in formalin-fixed paraffin-embedded samples (37-39). It detects most ESR2 isoforms derived from differential splicing variants, including the wildtype ESR2. As variants of ESR2 differ in function from the wildtype ESR2 (40, 41), future studies could potentially gain more detailed insight into how sex steroids influence colorectal carcinogenesis by using variant-specific antibodies.
In conclusion, the present study provides evidence that the use of exogenous hormones is associated with a decreased risk for ESR2-positive and not ESR2-negative colorectal cancer in women. These findings support the hypothesis from cell line and animal studies that the preventive effects of female sex hormones are at least in part mediated by ESR2. 
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